Last reviewed · How we verify
Ontak (E7777)
Ontak (E7777) is a CD25-directed cytotoxin, a small molecule drug developed by Eisai Inc. It targets the interleukin-2 receptor, a protein on the surface of certain cancer cells. Ontak is approved by the FDA for the treatment of primary cutaneous T-cell lymphoma and refractory peripheral T-cell lymphoma. It was first approved in 1999 and remains a patented product. As a cytotoxin, Ontak works by selectively killing cancer cells that express the interleukin-2 receptor.
At a glance
| Generic name | E7777 |
|---|---|
| Also known as | ONTAK® |
| Sponsor | Eisai |
| Drug class | CD25-directed Cytotoxin |
| Target | Interleukin-2 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1999 |
Approved indications
- Primary cutaneous T-cell lymphoma
- Refractory peripheral T-cell lymphoma
Common side effects
Key clinical trials
- Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL (PHASE1,PHASE2)
- T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors (PHASE1,PHASE2)
- A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (PHASE3)
- A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
- Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma (PHASE2)
- E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma (PHASE1)
- A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ontak CI brief — competitive landscape report
- Ontak updates RSS · CI watch RSS
- Eisai portfolio CI